Sorrento Therapeutics Inc (CE) News - SRNE

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option PR Newswire SAN DIEGO, Oct. 25, 2013 SAN DIEGO, Oct. 25, 2013 /PRNewswire/...

Venue Change

Fri, Oct 25, 2013 12:00 - Sorrento Therapeutics, Inc. (SRNE: Nasdaq) - Venue Change - The symbol, SRNE, no longer trades on OTC Link. As of Fri...

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain PR Newswire SAN DIEGO, Oct. 10, 2013 SAN DIEGO, Oct...

Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: ...

Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: From Concept to...

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personaliz...

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer...

Sorrento Therapeutics Completes IgDraSol Merger

Sorrento Therapeutics Completes IgDraSol Merger PR Newswire SAN DIEGO, Sept. 10, 2013 SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento...

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway Official Minutes from...

Sorrento Therapeutics Announces Reverse Split of Common Stock

Sorrento Therapeutics Announces Reverse Split of Common Stock PR Newswire SAN DIEGO, Aug. 1, 2013 SAN DIEGO, Aug. 1, 2013 /PRNewswire/...

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th Internation...

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine...

Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market

Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market PR...

Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology

Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology PR Newswire SAN DIEGO, June 6, 2013...

Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City

Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City PR Newswire SAN DIEGO, May 30, 2013 SAN...

Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued ...

Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Sorrento Therapeutics Inc (CE) (SRNE)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SRNE News

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option

Venue Change

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain

Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: ...

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personaliz...

Sorrento Therapeutics Completes IgDraSol Merger

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway

Sorrento Therapeutics Announces Reverse Split of Common Stock

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th Internation...

Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market

Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology

Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City

Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued ...

SRNE Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Sorrento Therapeutics Inc (CE) (SRNE) News

Sorrento Therapeutics Inc (CE) (SRNE)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SRNE News

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option

Venue Change

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain

Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: ...

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personaliz...

Sorrento Therapeutics Completes IgDraSol Merger

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway

Sorrento Therapeutics Announces Reverse Split of Common Stock

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th Internation...

Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market

Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology

Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City

Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued ...

SRNE Discussion

Your Recent History